SCHEMBL10132028

SCHEMBL10132028

CN(CCNC(=O)CCC(=O)NC1CC1)CC(=O)NC1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAOA P21397 1/20 0.38
POLB P06746 1/20 0.38
RECQL P46063 1/20 0.38
DNM1 Q05193 1/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMYD3 Q9H7B4 3/20 0.36
HPGD P15428 2/20 0.36
PKM P14618 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132037 0.94 RAB9A (0.40) ALDH1A1SMN1; SMN2POLBRECQLDNM1
SCHEMBL10132042 0.82 MAOA (0.40) ALDH1A1SMN1; SMN2MAOAPOLBRECQL
SCHEMBL10132083 0.79 MAOA (0.47) ALDH1A1SMN1; SMN2MAOAKMT2AHPGD
SCHEMBL16280974 0.75 DNM1 (0.42) ALDH1A1POLBDNM1KMT2AHPGD
SCHEMBL24754796 0.75 DNM1 (0.44) ALDH1A1POLBRECQLDNM1KMT2A
SCHEMBL10132099 0.74 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL29952336 0.74 LMNA (0.40) ALDH1A1SMN1; SMN2MAOAKMT2AHPGD
SCHEMBL854305 0.73 MAOA (0.42) ALDH1A1SMN1; SMN2MAOASMYD3MAPT
SCHEMBL854306 0.73 MAOA (0.42) ALDH1A1SMN1; SMN2MAOASMYD3MAPT
SCHEMBL10132085 0.73 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2KMT2ASMYD3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A ALDH1A1 4835/4885SMN1; SMN2 4722/4885MAOA 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.